期刊
WILEY INTERDISCIPLINARY REVIEWS-RNA
卷 12, 期 6, 页码 -出版社
WILEY
DOI: 10.1002/wrna.1662
关键词
cancer; clinical trials; diagnostics; microRNA; miR; miRNA; noncoding RNA; therapeutic; tumor
类别
资金
- National Cancer Institute [R01 CA221771, R21 CA226579, R37CA215427, R01CA240607]
The link between microRNAs and cancer has been established for almost two decades, with extensive research applied to various cancer types. These studies have led to significant advances in microRNA detection technology, biomarker development, and gene expression regulatory mechanisms, but translating these findings into clinical tools still faces challenges.
It has been almost two decades since the first link between microRNAs and cancer was established. In the ensuing years, this abundant class of short noncoding regulatory RNAs has been studied in virtually all cancer types. This tremendously large body of research has generated innovative technological advances for detection of microRNAs in tissue and bodily fluids, identified the diagnostic, prognostic, and/or predictive value of individual microRNAs or microRNA signatures as potential biomarkers for patient management, shed light on regulatory mechanisms of RNA-RNA interactions that modulate gene expression, uncovered cell-autonomous and cell-to-cell communication roles of specific microRNAs, and developed a battery of viral and nonviral delivery approaches for therapeutic intervention. Despite these intense and prolific research efforts in preclinical and clinical settings, there are a limited number of microRNA-based applications that have been incorporated into clinical practice. We review recent literature and ongoing clinical trials that highlight most promising approaches and standing challenges to translate these findings into viable microRNA-based clinical tools for cancer medicine. This article is categorized under: RNA in Disease and Development > RNA in Disease
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据